Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Abstract

The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.

Description

field of invention [0001] The present invention relates to compositions useful in the prevention and treatment of schizophrenia and similar psychiatric disorders. In particular, the invention relates to compositions comprising aryl-heterocyclic pharmaceutical compounds, such as ziprasidone. In one aspect of the invention, the composition is in the form of nanoparticles and also comprises at least one surface stabilizer. In another aspect, the invention also relates to novel dosage forms for the controlled delivery of aryl-heterocyclic pharmaceutical compounds, such as ziprasidone, and methods of preventing and treating schizophrenia and similar psychiatric disorders. Background of the invention [0002] Ziprasidone, the chemical name is 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-di Hydrogen-2H-indol-2-one, a benzothiazolylpiperazine derivative, is used as an antipsychotic agent in the treatment of psychiatric disorders such as schizophrenia, halluc...

AI Technical Summary

Problems solved by technology

This poor water solubility results in poor bioavailability

Images